Cytokinetics brings patent suit against Bristol Myers, escalating rivalry
Endpoints News reports Cytokinetics filed a patent infringement lawsuit against Bristol Myers Squibb, escalating competition in the cardiac myosin modulator space.
Cytokinetics is a late-stage biopharmaceutical company focused on discovering and developing muscle biology-directed therapies for diseases of impaired muscle function, including cardiac myosin modulators for heart failure and skeletal muscle activators for ALS and SMA.
Endpoints News reports Cytokinetics filed a patent infringement lawsuit against Bristol Myers Squibb, escalating competition in the cardiac myosin modulator space.